Sclerosis, Systemic clinical trials at UC Health

• A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

  Sorry, in progress, not accepting new patients

  This study is the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study is to see how GLPG1690 is tolerated in participants with systemic sclerosis and whether there are any side effects in a long-term treatment period.

  at UCLA

Last updated: July 6, 2020